ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

ÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïÃâÒßÖƱ¸¿¹ÒȵºËص¥¿Ë¡¿¹Ìå_ҩѧרҵ±ÏÒµÂÛÎÄ

·¢²¼Ê±¼ä£º2014-11-09 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
 ¡¾ÕªÒª¡¿  Ä¿µÄ  ÖƱ¸¿¹ÒȵºËص¥¿Ë¡¿¹Ì壨mAb£©¡£·½·¨  ÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïÃâÒßBALB/cСÊóÖƱ¸ÃâÒßƢϸ°û£¬ÔËÓÃÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ½«ÆäÓëСÊó¹ÇËèÁöϸ°ûSP2/0Èںϡ£½á¹û  ½¨Á¢ÁË7Öê·ÖÃÚ¿¹ÒȵºËØmAbµÄÔÓ½»Áöϸ°ûϵ£¬ÃüÃûΪA¡¢B¡¢C¡¢D¡¢E¡¢FºÍG£»7ÖêmAbµÄIgÑÇÀà·Ö±ðΪIgM¡¢IgM¡¢IgM¡¢IgG2b¡¢IgG1¡¢IgG1ºÍIgG1£»ÔÚ¼ÐÐÄELISAÊÔÑéÖУ¬7ÖêmAb¾ùÄÜÓëÈË¡¢Å£ºÍÖíÒȵºËØ·¢ÉúÌØÒìÐÔÃâÒß·´Ó¦£»ÔÚÃâÒßÓ¡¼£ÊÔÑéÖУ¬7ÖêmAb¾ùÄÜÓëÖØ×éÈËÒȵºËØÔ­ÀàËÆÎï½áºÏ³ÊÏÖÒ»Ìõµ°°×Ó¡¼£´ø¡£½áÂÛ  7ÖêmAb¶ÔÈË¡¢Å£ºÍÖíÒȵºËؾù¾ßÓÐÃâÒß·´Ó¦ÐÔ£¬¿ÉÓÃÓÚÈ˺Ͷ¯ÎïÒȵºËصIJⶨºÍ´¿»¯¡£     ¡¾¹Ø¼ü´Ê¡¿  µ¥¿Ë¡¿¹Ì壨mAb£©£»ÒȵºËØ£»ÖØ×éÈËÒȵºËØÔ­ÀàËÆÎï     Development of monoclonal antibodies against insulin by immunization with recombinant human proinsulin analog        ¡¾Abstract¡¿  Objective  To prepare monoclonal antibody (mAb) against insulinMethods  Spleen cells from BALB/c mice immunized with recombinant human proinsulin analog were fused with SP2/0 myeloma cells by using hybridoma techniques.Results Seven hybridomas secreting mAb against insulin were established and designated A, B, C, D, E, F and G. The subclass of the seven mAb was IgM, IgM, IgM, IgG2b, IgG1, IgG1 and IgG1 respectively. The seven mAb could specifically react with insulin derived from human, cattle or pig in sandwich ELISA. The specific reaction of each mAb with recombinant human proinsulin analog was confermed by immunoblotting assay, only one stained protein band appeared on the transferred film.Conclusion   The seven mAb are immunological specific to insulin derived from human, cattle or swine, and are available to the detection and purification of insulin.     ¡¾Key words¡¿  monoclonal antibody (mAb); insulin; recombinant human proinsulin analog     ÒȵºËØÊǾßÓÐÖØÒªÉúÀí¹¦ÄܵÄÒ»ÖÖ¶àëÄÀ༤ËØ£¬ÔÚÖÎÁÆÌÇÄò²¡·½Ãæ¾ßÓÐÖØÒªÓÃ;¡£ÒȵºËØ¿¹ÌåÊÇÒȵºËزⶨºÍ´¿»¯Ëù±ØÐèµÄÃâÒßѧÊÔ¼Á¡£Îª´Ë½øÐÐÁ˱¾Ñо¿¡£     1  Óë·½·¨     1.1  ¾úÖÖ¡¢ÖÊÁ£ºÍϸ°û  ´ó³¦¸Ë¾úJM109¡¢Ð¡Êó¹ÇËèÁöSP2/0ϸ°ûϵ¡¢º¬ÓЦËÊɾúÌåPRPL´®ÁªÆô¶¯×ÓµÄÈËÒȵºËØÔ­ÀàËÆÎBKRA£©»ùÒò±í´ïÖÊÁ£pBV- BKRAÓɱ¾¿ÎÌâ×é¹¹½¨ºÍ±£´æ£Û1£Ý¡£     1.2  ÃâÒßѪÇåµÄÖƱ¸  ÊÕ¼¯´ó³¦¸Ë¾úJM109ÅàÑøÎÀëÐijÁµí¾úÌ壬Óó¬Éù²¨ÆÆË飬¼Ó¸£ÊÏ×ô¼ÁÈ黯ºó£¬¾­Æ¤ÏÂ×¢ÉäÃâÒßÍã¬ÖƱ¸JM109ÃâÒßѪÇå¡£     1.3  ÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïµÄÖƱ¸  ÓÃpBV-     BKRAת»¯JM109£Û1¡½¡£È¡µ¥¸ö¾úÂ䣬30¡æÅàÑø14h£¬ÒÔ20%½ÓÖÖÔÚº¬¿¨ÄÇùËØ£¨Kan£©µÄÐÂÏÊLBÅàÑøÒºÖУ¬42¡æÕñµ´ÅàÑø4h£¬¸ßËÙÀëÐijÁµí¾úÌå¡£²ÎÕÕÎÄÏ×£Û2¡½·ÖÀë°üº­Ì壬ÓöþÏõ»ù±½»ÇËáÄÆ´¦Àí£Û3¡½ºó×÷ΪBALB/cСÊóÃâÒß¿¹Ô­¡£     1.4  ÃâÒßÊó  ½«ÖƱ¸µÄÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïÓëµÈÁ¿¸£ÊÏÍêÈ«×ô¼Á»ìºÏÈ黯£¬¾­¸¹Ç»×¢ÉäÃâÒß6ÖÜÁäµÄBALB/cСÊó£¬20mg/£¨´Î¡¤Ö»£©£¬ÃâÒß2´Î£¬¼ä¸ô2ÖÜ¡£ÔÚϸ°ûÈÚºÏÇ°3¡«4Ìì, ¼ÓÇ¿ÃâÒß1´Î¡£     1.5  ϸ°ûÈںϠ ²ÎÕÕÎÄÏ×£Û4¡½£¬ÓÃÃâÒßµÄBALB/cСÊóÖƱ¸Æ¢Ï¸°û£¬ÓëСÊó¹ÇËèÁöϸ°ûSP2/0Èںϡ£     1.6  ÔÓ½»Áöϸ°ûµÄɸѡÓë¿Ë¡»¯  ²ÉÓüä½ÓÒÖÖÆELISA·½·¨¡£ÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎï°ü±»ELISA·´Ó¦°å£¬10%µÄJM109ÃâÒßѪÇå·â±Õ£¬¼ÓÈëÔÓ½»Áöϸ°ûÅàÑøÉÏÇåÒºÓëÖ®·´Ó¦£¬ÔÙÓëÀ±¸ù¹ýÑõ»¯Îïø£¨HRP£©±ê¼ÇµÄÍÿ¹ÊóIgG·´Ó¦£¬ÏÔÉ«¡£´ÓÁ½´Î¼ì²â¾ùΪÑôÐÔµÄÔÓ½»Áöϸ°û¿×ÖÐÑ¡È¡7¸öÑôÐÔ¿×£¬ÓÃÓÐÏÞÏ¡ÊÍ·¨½øÐпË¡»¯¡£     1.7  µ¥¿Ë¡¿¹ÌåµÄÖƱ¸  ½«µ¥¿Ë¡»¯µÄÑôÐÔÔÓ½»Áöϸ°ûÀ©´óÅàÑø£¬°´5¡Á106/Ö»µÄϸ°ûÁ¿×¢ÉäÓÚ7¡«10ÌìÇ°Ô¤Ïȸ¹Ç»×¢ÉäÎÞ¾úҺ״ʯÀ¯µÄBALB/cСÊó¸¹Ç»ÄÚ£¬ÓÕÉú¸¹Ë®£¬ÖƱ¸mAb¡£     1.8  µ¥¿Ë¡¿¹ÌåµÄЧ¼Û  ÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎï°ü±»ELISA·´Ó¦°å£¬ÒÔ³£¹æ¼ä½ÓELISA·Ö±ð²â¶¨¸÷µ¥¿Ë¡»¯µÄÔÓ½»Áöϸ°ûÅàÑøÉÏÇåÒººÍÓÕÉú¸¹Ë®ÖеÄmAbЧ¼Û¡£     1.9  µ¥¿Ë¡¿¹ÌåµÄ¼ø¶¨     1.9.1  ÑÇÀà  ½«Å¨Ëõ10±¶ÒÔÉϵÄÔÓ½»Áöϸ°ûÅàÑøÉÏÇåÒº»òÔÓ½»Áöϸ°ûÓÕÉú¸¹Ë®£¬Óÿ¹ÊóIgÑÇÀàѪÇ壨Sigma²úÆ·£©£¬ÒÔÇí֬˫À©É¢ÊÔÑé¼ø¶¨mAbµÄÑÇÀà¡£     1.9.2  ÌØÒìÐÔ     1.9.2.1  ¼ÐÐÄELISA  ÓÃ7ÖêmAb×÷Ϊ²¶×½¿¹Ìå·Ö±ð°ü±»ELISA·´Ó¦°å£¬ÒÔÈËÒȵºËØ£¨Sigma²úÆ·£©¡¢Å£ÒȵºËØ£¨Sigma²úÆ·£©¡¢ÖíÒȵºËØ£¨ÄϾ©Éú»¯ÖƳ§²úÆ·£©×÷Ϊ±»²¶×½Îï·Ö±ðÓëÖ®·´Ó¦£¬ÔÙ¼ÓÈëÀ±¸ù¹ýÑõ»¯Îïø£¨HRP£©±ê¼ÇµÄ¿¹ÒȵºËص¥¿Ë¡¿¹Ì壨Sigma²úÆ·£©·´Ó¦ÏÔÉ«£¬7ÖêmAbÄÜ·ñ²¶×½ÒȵºËØ¡£     1.9.2.2  ÃâÒßÓ¡¼£ÊÔÑé  ²ÉÓÃÃâÒßÓ¡¼£·¨£Û5¡½·ÖÎö¡£ÖØ×é¾úÓÕµ¼±í´ïºó£¬½«¾úÌå½øÐÐSDS-PAGE£¬µçӾתÒƵ½ÏõËáÏËάËØĤÉÏ£¬ÓÃ7ÖêmAb·Ö±ðÓëתÒÆĤ·´Ó¦ºó£¬ÔÙ¼Ó¼îÐÔÁ×Ëáø£¨AP£©±ê¼ÇµÄɽÑò¿¹ÊóIgGÓëתÒÆĤ·´Ó¦£¬ÏÔÉ«¡£ÊµÑéͬ²½ÉèÁ¢JM109¾úÓëpBV220ת»¯¾ú¶ÔÕÕ¡£     2  ½á¹û     2.1  ÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïµÄÖƱ¸  ÓÃSDS-PAGEºÍÄý½ºÉ¨Ãè·ÖÎö£¬°üº­ÌåÖÐÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïµÄº¬Á¿´ïµ½80%£¨Í¼1£©¡£ ͼ1  pBV-BKRAµÄÓÕµ¼±í´ïÓëmAb±í´ï£¨ÂÔ£©     2.2  ϸ°ûÈÚºÏÓë¿Ë¡»¯  ÈÚºÏϸ°ûµÄÑôÐÔÂÊΪ2.4%£¨7/288£©¡£´ÓÖÐÑ¡È¡7¸öÑôÐÔ¿×½øÐпË¡»¯£¬¾­3´Î¿Ë¡ºó£¬ËùÓÐϸ°ûÉú³¤¿×¾ù³ÊÑôÐÔ·´Ó¦¡£     2.3  µ¥¿Ë¡¿¹ÌåµÄЧ¼ÛºÍÑÇÀà  ¼ä½ÓELISA·¨²â¶¨7ÖêmAbϸ°ûÅàÑøÉÏÇåÒºÖеĿ¹ÌåЧ¼ÛΪ102£¬¶øÓÕÉú¸¹Ë®ÖеĿ¹ÌåЧ¼Û´ïµ½105¡«106¡£IgÑÇÀà¼ø¶¨½á¹û¼û±í1¡£±í1  7Ö꿹ÒȵºËØmAbµÄЧ¼ÛºÍIgÑÇÀࣨÂÔ£©     2.4  µ¥¿Ë¡¿¹ÌåµÄÌØÒìÐÔ  ÔÚ¼ÐÐÄELISAÊÔÑéÖУ¬7ÖêmAb¾ùÄܲ¶×½µ½ÈË¡¢Å£ºÍÖíÒȵºËØ£»ÔÚÃâÒßÓ¡¼£ÊÔÑéÖУ¬7ÖêmAb¾ùÄÜÓëÖØ×éÈËÒȵºËØÔ­ÀàËÆÎ·Ö×ÓÁ¿12KD£©½áºÏ³ÊÏÖÒ»Ìõµ°°×Ó¡¼£´ø£¨Í¼1-A¡«G£©¡£±íÃ÷ÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïÃâÒßÖƱ¸µÄ7ÖêmAb¶ÔÈË¡¢Å£ºÍÖíÒȵºËؾù¾ßÓÐÌØÒìµÄÃâÒß·´Ó¦ÐÔ¡£     3  ÌÖÂÛ     ±¾ÊµÑéÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎïÃâÒßBALB/cÊ󣬳ɹ¦µØ»ñµÃÁË7Ö꿹ÒȵºËØmAb£¬¿ÉÓëÈË¡¢Å£¡¢ÖíÒȵºËØ·¢ÉúÌØÒìÐÔÃâÒß·´Ó¦£¬ÎªÒȵºËصIJⶨºÍ´¿»¯Ôö¼ÓÁËеĿ¹ÌåÑ¡Ôñ¡£     ÖƱ¸ÌìÈ»ÒȵºËØ´¿Æ·±È½ÏÀ§ÄÑ¡£Òò´Ë£¬±¾ÊµÑéÓÃÖØ×éÈËÒȵºËØÔ­ÀàËÆÎï×÷ΪÃâÒß¿¹Ô­£¬ÖƱ¸ºÍ´¿»¯¹ý³Ì¼ò±ã£¬ÔÚÃâÒßÇ°£¬¶ÔÆäÓöþÏõ»ù±½»ÇËáÄƽøÐÐÁË´¦Àí£¬Ä¿µÄÊÇÌá¸ßÃâÒßÔ­ÐÔ£Û3¡½¡¢ÔöÇ¿BALB/cÊóµÄÃâÒß·´Ó¦£»ÔÚɸѡ¼ì²âʱ²ÉÓÃÁËͬԴËÞÖ÷¾úÃâÒßѪÇåÒÖÖÆELISA£¬ÒÔ½µµÍ»òÏû³ýɸѡ¼ì²â¹ý³ÌÖеķÇÌØÒìÐÔ·´Ó¦¡£½á¹û±íÃ÷£¬ÒÔÉÏ´ëÊ©¶ÔÌá¸ßʵÑéЧÂÊÊÇÓÐñÔÒæµÄ¡£     ¡¾²Î¿¼ÎÄÏס¿     1      ·¿µÂÐË£¬ÍõÓÀɽ£¬ÖÜ×Ú°²£¬µÈ. ÈËÒȵºËØÔ­ÀàËÆÎBKRA£©»ùÒòµÄºÏ³ÉÓë±í´ï. ÖйúÉúÎﻯѧÓë·Ö×ÓÉúÎïѧѧ±¨£¬1998£¬14£¨5£©£º518-524.     2  ¬ʥ¶°. ÏÖ´ú·Ö×ÓÉúÎïѧʵÑé¼¼Êõ. ±±¾©£º¸ßµÈ³ö°æÉ磬1993£¬380.     3  Öìƽ£¬·ëÊéÕÂ. ¿¹ÌåʵÑé¼¼Êõ. ³¤´º£º³¤´º³ö°æÉ磬1994£¬117-118.     4  ÁõÐãèó. µ¥¿Ë¡¿¹ÌåÔÚÉϵÄÓ¦ÓÃ. ºÏ·Ê£º°²»Õ¿Æѧ¼¼Êõ³ö°æÉ磬1994£¬30.     5  ½ð¶¬Ñã, ÀèÃÏ·ã, ºîÔƵÂ,Òë. ·Ö×Ó¿Ë¡ʵÑéÖ¸ÄÏ,µÚ2°æ.±±¾©£º¿Æѧ³ö°æÉ磬1992£¬889-897.
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö